IDXX
Neutral signalScored 2026-10-18 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
IDEXX Laboratories, Inc.
- Nom
- IDEXX Laboratories, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $44.2B
- Employés
- 11,000
- PDG
- Michael Erickson
- Site web
- https://www.idexx.com
- Marché
- ELANMRKNEOGZTS
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,172,178
Avg sell (VWAP, 90d window) $532.08 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-18 17:07:39
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Kingsley Lawrence D | Sell · S | 2,203 | $532.08 | $1,172,178 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-09-11 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-09-04 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-01-13 | April McClain Delaney | Sale (Full) | $1,001 - $15,000 |
| 2025-12-02 | April McClain Delaney | Sale (Partial) | $1,001 - $15,000 |
| 2025-10-29 | April McClain Delaney | Sale (Partial) | $1,001 - $15,000 |
| 2025-10-16 | April McClain Delaney | Sale (Partial) | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-04 | Byron Donalds | Purchase | $1,001 - $15,000 |
| 2025-09-04 | Byron Donalds | Purchase | $1,001 - $15,000 |
| 2025-08-07 | April McClain Delaney | Sale | $1,001 - $15,000 |
| 2025-08-01 | April McClain Delaney | Sale | $1,001 - $15,000 |
| 2025-07-09 | April McClain Delaney | Sale (Partial) | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $100,001 - $250,000 |
| 2025-04-09 | April McClain Delaney | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Jefferson Shreve | Purchase | $50,001 - $100,000 |
| 2025-04-07 | April McClain Delaney | Purchase | $1,001 - $15,000 |
| 2025-04-04 | April McClain Delaney | Purchase | $1,001 - $15,000 |
| 2025-04-01 | April McClain Delaney | Purchase | $1,001 - $15,000 |
| 2025-03-14 | April McClain Delaney | Purchase | $1,001 - $15,000 |
| 2025-03-13 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-02-25 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-26 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-10-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-26 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-09-26 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-08-24 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-08-24 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $1,001 - $15,000 |
| 2020-10-09 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-08-11 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-06-10 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-04-09 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-06-03 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2019-02-27 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2019-02-26 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-18 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
IDXX combines strong fundamentals (high margins, excellent ROIC, healthy cash flow) with a moderate event-driven catalyst anchored by the CoVetAI acquisition and management's reaffirmation of long-term growth targets at…
The first sentence of the analysis written for IDXX on 2026-10-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.17 · operating margin 32%
Recent news
- 2026-10-17 IDEXX Laboratories, Inc. $IDXX Stock Bought by Assenagon Asset Management S.A. Assenagon Asset Management S.A. raised its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 39.9% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 256,362 shares of the company''s stock after buying an additional 73,129 shares during the quarter. Assenagon Asset Management S.A. owned about 0.33%
- 2026-10-01 IDEXX Laboratories to Release 2026 Third Quarter Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX websi.
- 2026-09-30 Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories Transaction marks the first realization from the now closed specialist animal health fund''s inaugural vehicle CHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company''s acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX).
- 2026-09-23 Should You Continue to Hold IDXX Stock in Your Portfolio? IDEXX''s CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
- 2026-09-21 IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets IDEXX Laboratories (NASDAQ: IDXX) executives highlighted the company''s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits. Chief Executive Officer Mike Erickson said the company had an "exceptional" second quarter and a strong start to
- 2026-09-21 IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference IDEXX Laboratories (NASDAQ: IDXX) executives reiterated the company''s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Officer Mike Erickson said IDEXX had an "exceptional Q2" and a strong start to the year, prompting the company to raise
- 2026-09-20 IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets IDEXX Laboratories NASDAQ: IDXX executives highlighted the company''s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits.
- 2026-09-20 IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference IDEXX Laboratories NASDAQ: IDXX executives reiterated the company''s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers.
- 2026-09-17 IDEXX Stock Gains Following the Acquisition of CoVet IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
- 2026-09-17 IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | |
| Ebit Margin | 31.7% | 29.3% | 30.1% | 26.7% | 29.0% | |
| Ebitda Margin | 35.0% | 32.7% | 33.3% | 30.1% | 32.3% | |
| Operating Profit Margin | 31.6% | 29.0% | 30.0% | 26.7% | 29.0% | |
| Pretax Profit Margin | 30.8% | 28.5% | 29.0% | 25.5% | 28.1% | |
| Continuous Operations Profit Margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | |
| Net Profit Margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | |
| Bottom Line Profit Margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | |
| Current Ratio | 1.167 | 1.311 | 1.571 | 0.891 | 1.252 | |
| Quick Ratio | 0.838 | 0.953 | 1.172 | 0.594 | 0.899 | |
| Solvency Ratio | 0.690 | 0.599 | 0.541 | 0.370 | 0.486 | |
| Cash Ratio | 0.157 | 0.270 | 0.477 | 0.091 | 0.189 | |
| Price To Earnings Ratio | 51.369 | 38.388 | 54.577 | 50.241 | 75.339 | |
| Price To Earnings Growth Ratio | 2.305 | 6.507 | 2.162 | -7.082 | 2.676 | |
| Forward Price To Earnings Growth Ratio | 2.305 | 6.507 | 2.162 | -7.082 | 2.676 | |
| Price To Earnings Diluted Ratio | 51.722 | 38.748 | 55.174 | 50.804 | 76.565 | |
| Price To Earnings Diluted Growth Ratio | 2.290 | 6.390 | 2.182 | -7.665 | 2.718 | |
| Price To Book Ratio | 33.754 | 21.372 | 31.057 | 56.042 | 81.306 | |
| Price To Sales Ratio | 12.591 | 8.748 | 12.594 | 10.131 | 17.448 | |
| Price To Free Cash Flow Ratio | 51.441 | 42.722 | 59.655 | 86.554 | 88.209 | |
| Price To Operating Cash Flow Ratio | 45.997 | 36.701 | 50.861 | 62.828 | 74.252 | |
| Debt To Assets Ratio | 0.321 | 0.300 | 0.327 | 0.535 | 0.423 | |
| Debt To Equity Ratio | 0.671 | 0.619 | 0.719 | 2.415 | 1.494 | |
| Debt To Capital Ratio | 0.402 | 0.382 | 0.418 | 0.707 | 0.599 | |
| Long Term Debt To Capital Ratio | 0.229 | 0.220 | 0.296 | 0.533 | 0.529 | |
| Financial Leverage Ratio | 2.087 | 2.064 | 2.196 | 4.512 | 3.532 | |
| Working Capital Turnover Ratio | 16.444 | 8.902 | 17.885 | 116.617 | 9.569 | |
| Operating Cash Flow Ratio | 1.025 | 0.870 | 0.953 | 0.439 | 0.989 | |
| Operating Cash Flow Sales Ratio | 0.274 | 0.238 | 0.248 | 0.161 | 0.235 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.894 | 0.859 | 0.853 | 0.726 | 0.842 | |
| Debt Service Coverage Ratio | 2.309 | 2.347 | 2.732 | 1.201 | 4.947 | |
| Interest Coverage Ratio | 35.542 | 36.159 | 26.385 | 22.549 | 31.268 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.356 | 2.224 | 2.789 | 0.830 | 5.088 | |
| Operating Cash Flow Coverage Ratio | 1.094 | 0.941 | 0.849 | 0.369 | 0.733 | |
| Capital Expenditure Coverage Ratio | 9.449 | 7.096 | 6.784 | 3.648 | 6.320 | |
| Dividend Paid And Capex Coverage Ratio | 9.449 | 7.096 | 6.784 | 3.648 | 6.320 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 36.537 | 27.271 | 38.368 | 34.964 | 54.803 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.8% | ▲0.8% | ▲1.6% |
| Ebit Margin | 31.7% | ▲2.4% | ▲2.3% |
| Ebitda Margin | 35.0% | ▲2.3% | ▲2.3% |
| Operating Profit Margin | 31.6% | ▲2.6% | ▲2.4% |
| Pretax Profit Margin | 30.8% | ▲2.3% | ▲2.4% |
| Continuous Operations Profit Margin | 24.6% | ▲1.8% | ▲1.8% |
| Net Profit Margin | 24.6% | ▲1.8% | ▲1.8% |
| Bottom Line Profit Margin | 24.6% | ▲1.8% | ▲1.8% |
| Current Ratio | 1.167 | ▼-0.144 | ▼-0.072 |
| Quick Ratio | 0.838 | ▼-0.115 | ▼-0.053 |
| Solvency Ratio | 0.690 | ▲0.091 | ▲0.153 |
| Cash Ratio | 0.157 | ▼-0.113 | ▼-0.080 |
| Price To Earnings Ratio | 51.369 | ▲12.981 | ▼-2.614 |
| Price To Earnings Growth Ratio | 2.305 | ▼-4.202 | ▲0.992 |
| Forward Price To Earnings Growth Ratio | 2.305 | ▼-4.202 | ▲0.992 |
| Price To Earnings Diluted Ratio | 51.722 | ▲12.975 | ▼-2.880 |
| Price To Earnings Diluted Growth Ratio | 2.290 | ▼-4.100 | ▲1.107 |
| Price To Book Ratio | 33.754 | ▲12.382 | ▼-10.953 |
| Price To Sales Ratio | 12.591 | ▲3.843 | ▲0.288 |
| Price To Free Cash Flow Ratio | 51.441 | ▲8.719 | ▼-14.275 |
| Price To Operating Cash Flow Ratio | 45.997 | ▲9.296 | ▼-8.131 |
| Debt To Assets Ratio | 0.322 | ▲0.022 | ▼-0.060 |
| Debt To Equity Ratio | 0.671 | ▲0.052 | ▼-0.513 |
| Debt To Capital Ratio | 0.402 | ▲0.019 | ▼-0.100 |
| Long Term Debt To Capital Ratio | 0.229 | ▲0.009 | ▼-0.133 |
| Financial Leverage Ratio | 2.087 | ▲0.023 | ▼-0.791 |
| Working Capital Turnover Ratio | 16.444 | ▲7.543 | ▼-17.439 |
| Operating Cash Flow Ratio | 1.026 | ▲0.155 | ▲0.170 |
| Operating Cash Flow Sales Ratio | 0.274 | ▲0.035 | ▲0.043 |
| Free Cash Flow Operating Cash Flow Ratio | 0.894 | ▲0.035 | ▲0.059 |
| Debt Service Coverage Ratio | 2.309 | ▼-0.038 | ▼-0.399 |
| Interest Coverage Ratio | 35.542 | ▼-0.616 | ▲5.162 |
| Short Term Operating Cash Flow Coverage Ratio | 2.356 | ▲0.132 | ▼-0.302 |
| Operating Cash Flow Coverage Ratio | 1.094 | ▲0.152 | ▲0.296 |
| Capital Expenditure Coverage Ratio | 9.449 | ▲2.353 | ▲2.790 |
| Dividend Paid And Capex Coverage Ratio | 9.449 | ▲2.353 | ▲2.790 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 36.537 | ▲9.266 | ▼-1.852 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $54.19B | $34.10B | $46.11B | $34.11B | $56.10B | |
| Enterprise value | $55.08B | $34.79B | $46.72B | $35.47B | $56.99B | |
| EV / Sales | 12.80x | 8.93x | 12.76x | 10.53x | 17.72x | |
| EV / Op. cash flow | 46.76x | 37.45x | 51.54x | 65.33x | 75.42x | |
| EV / Free cash flow | 52.29x | 43.60x | 60.45x | 90.00x | 89.60x | |
| EV / EBITDA | 36.54x | 27.27x | 38.37x | 34.96x | 54.80x | |
| Net debt / EBITDA | 0.59x | 0.55x | 0.50x | 1.34x | 0.85x | |
| Current ratio | 1.17x | 1.31x | 1.57x | 0.89x | 1.25x | |
| Income quality | 1.11x | 1.05x | 1.07x | 0.80x | 1.01x | |
| Graham number | $77 | $68 | $64 | $36 | $40 | |
| Graham net-net | -$11 | -$10 | -$9 | -$18 | -$13 | |
| Tax burden | 80.0% | 80.0% | 79.6% | 79.0% | 82.5% | |
| Interest burden | 97.2% | 97.3% | 96.2% | 95.6% | 96.8% | |
| Working capital | $191.4M | $332.0M | $543.7M | -$134.3M | $192.1M | |
| Invested capital | $1.59B | $1.68B | $1.81B | $1.09B | $1.34B | |
| Return on assets | 31.6% | 27.0% | 25.9% | 24.7% | 30.6% | |
| Operating ROA | 40.9% | 34.4% | 36.5% | 34.7% | 39.4% | |
| Return on tangible assets | 37.5% | 32.0% | 30.1% | 29.7% | 37.6% | |
| Return on equity | 66.0% | 55.7% | 56.9% | 111.6% | 107.9% | |
| Return on invested capital | 40.3% | 33.9% | 32.9% | 32.5% | 41.8% | |
| Return on capital employed | 61.8% | 50.7% | 47.5% | 59.5% | 55.7% | |
| Earnings yield | 2.0% | 2.6% | 1.8% | 2.0% | 1.3% | |
| Free cash flow yield | 1.9% | 2.3% | 1.7% | 1.2% | 1.1% | |
| Capex / Op. cash flow | 10.6% | 14.1% | 14.7% | 27.4% | 15.8% | |
| Capex / Depreciation | 85.9% | 100.8% | 116.3% | 133.0% | 114.3% | |
| Capex / Sales | 2.9% | 3.4% | 3.7% | 4.4% | 3.7% | |
| SG&A / Sales | 24.4% | 26.4% | 24.6% | 25.3% | 24.8% | |
| R&D / Sales | 5.8% | 5.6% | 5.2% | 7.6% | 5.0% | |
| Stock comp / Sales | 0.0% | 1.5% | 1.6% | 1.5% | 1.2% | |
| Intangibles / Total assets | 15.6% | 15.7% | 13.8% | 16.7% | 18.8% | |
| Days sales outstanding | 59d | 53d | 53d | 53d | 48d | |
| Days payables outstanding | 25d | 27d | 27d | 30d | 32d | |
| Operating cycle | 143d | 144d | 147d | 152d | 122d | |
| Cash conversion cycle | 118d | 117d | 120d | 122d | 90d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years